An increasing number of drugs of European origin have been in-licensed to Chinese biotechnology companies.
Over the last five years, a steady increase in the number of yearly in-licensed assets from Europe can be observed. Whereas only 30 drugs were in-licensed in 2016, the number more than quadrupled in 2021 (YTD) to 121.
Most sought-after assets have been in orphan diseases, oncology and CNS.
About FCF Life Sciences
FCF Life Sciences advises leading healthcare companies in Europe on financing transactions (equity, debt, and licensing) with regional and international investors. Our team consists of science-driven industry and finance experts with a strong track record in managing financing processes. We thrive to maximize the efficiency in the fundraising process and increase its closing probability.
Learn more about FCF Life Sciences, click here.
We closely track the activity in the financial markets and are passionate about capital markets research. Not every idea or research question make it into the final selection for our publications. However, we generate interesting information on financing trends in Life Sciences sector, which we would like to share in our blog.
To hear from us on the latest insights, please sign up here: